Does Podoplanin (PDPN) Reflect the Involvement of the Immunological System in Coronary Artery Disease Risk? A Single-Center Prospective Analysis
Authors:
- Tomasz UrbanowiczTomasz Urbanowicz
- Joanna Rupa-MatysekJRJoanna Rupa-Matysek
- Ewelina WojtasińskaEWEwelina Wojtasińska
- Beata KrasińskaBKBeata Krasińska
- Maciej ZielińskiMZMaciej Zieliński
- Malwina GrobelnaMGMalwina Grobelna
- Paweł ZawadzkiPZPaweł Zawadzki
- Ryszard StaniszewskiRSRyszard Staniszewski
- Zbigniew KrasińskiZKZbigniew Krasiński
- Elżbieta PaszyńskaElżbieta Paszyńska
- Andrzej TykarskiATAndrzej Tykarski
Open Access
- 15 December 2025
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (24) , 12051
Abstract
Coronary artery disease remains a significant global health challenge, driven by a multifactorial pathophysiology, including immunological activation. The identification and management of potential risk factors are crucial for improving prevention opportunities. In this study, the role of novel, innate immune system response markers, such as podoplanin 38, in atherosclerosis was investigated. A total of 150 consecutive patients (87 (58%) male; median age of 68 (61–76) years) with chronic coronary symptoms (anginal equivalent, e.g., exertional dyspnea) who underwent clinical evaluation and de novo coronary angiography for a prospective single-center analysis were included. Demographic and clinical data, combined with echocardiographic and coronary angiography results, were analyzed in conjunction with laboratory results from admission, including serum podoplanin (PDPN) concentrations. Serum PDPN concentrations were significantly lower in the coronary artery disease group (238 (174–360) pg/mL) compared to the control group (428 (207–1381) pg/mL, p = 0.002). A negative correlation was observed between PDPN and the number of involved coronary arteries in the atherosclerotic process (R = −0.27, p < 0.01). In diabetic populations, glycemic hemoglobin (Hb1Ac) is correlated with the podoplanin concentration (r = −0.51, p = 0.001). A correlation between PDPN and the left ventricular ejection fraction was noted in both the control (r = 0.33, p < 0.01) and CAD groups (r = 0.37, p < 0.001). Podoplanin (PDPN) can be considered a novel marker for coronary atherosclerosis. Low serum podoplanin concentrations characterized patients with coronary artery disease.Keywords
This publication has 57 references indexed in Scilit:
- Lymph node fibroblast phenotypes and immune crosstalk regulated by podoplanin activityCell Reports, 2025
- Investigating the landscape of immune-related genes and immunophenotypes in atherosclerosis: A bioinformatics Mendelian randomization studyBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2024
- Podoplanin and its multifaceted roles in mammalian developmental programCells & Development, 2024
- Light deficiency in Apoe−/−mice increases atheroma plaque size and vulnerability by modulating local immunityBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2024
- The effect of continuous glucose monitoring-guided glycemic control on progression of coronary atherosclerosis in type 2 diabetic patients with coronary artery disease: The OPTIMAL randomized clinical trialJournal of Diabetes and its Complications, 2023
- PDPN positive CAFs contribute to HER2 positive breast cancer resistance to trastuzumab by inhibiting antibody-dependent NK cell-mediated cytotoxicityDrug Resistance Updates, 2023
- A Role of the Podoplanin-CLEC-2 Axis in Promoting Inflammatory Response After Ischemic Stroke in MiceNeurotoxicity Research, 2020
- Podoplanin-Expressing Macrophages Promote Lymphangiogenesis and Lymphoinvasion in Breast CancerCell Metabolism, 2019
- Circulating inflammation markers and prostate cancerThe Prostate, 2019
- Emerging roles of podoplanin in vascular development and homeostasisFrontiers of Medicine, 2015